Equity Research European Pharmaceuticals & Life Sciences 27 December 2024 Novo Nordisk Weekly US diabetes & obesity market tracker Implications for Novo in 4Q24: IQVIA data reported 7.60mn/0.78mn/2.69mn TRx for Ozempic/ Rybelsus and Wegovy, respectively, in 3Q24. Based on the weekly data QTD and conservatively assuming flat to 1% w/w growth for the balance of the quarter, we expect 4Q24 total written scripts to come in at ~7.64mn/ 0.75mn/ 2.90mn for Ozempic/Rybelsus/Wegovy (+0.5% /-3.7% / +7.8% growth q/q). ...

. AI 在全球发展中的 PLAYBOOK TABLE OF CONTENTS - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Introduction — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — 行政摘要 — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — ...